



Media Releases » Torrent Pharma announces Q1 FY 2016-17 Results.

July 27th, 2016

Financial Highlights	Q1 FY 16-17	Q1 FY 15-16	Growth
Revenues	1,545	1,947	-21%
EBIDTA	462	985	-53%
%Revenues	30%	51%	
PAT (after Exceptional Items)	292	650	-55%
%Revenues	19%	33%	
EPS	17.3	38.4	-55%

All amounts in ₹ crores except per share data

Ahmedabad based Pharmaceuticals major, Torrent Pharmaceuticals Limited, today released its financial results for the Quarter ended 30th June 2016.

Quarterly Financials

- For Q1 FY 2016-17 revenues were at Rs. 1,545 crores as against Rs. 1,947 crores during the same period last year.
- EBIDTA for Q1 FY 2016-17 was at Rs. 462 crores as against Rs.

985 crores during the same period last year.

- PAT for Q1 2016-17 was at Rs. 292 crores as against Rs.650 crores during the same period last year.
- Previous period include exceptional revenues and profits which was primarily on account of the launch of a new product in US market, which had limited competition.
- Research and development spend during the quarter was up by 62%, from Rs. 56 crores in the same period previous year to Rs. 91 crores.

Q1 PERFORMANCE HIGHLIGHTS

India Business

- Domestic formulation business recorded revenues of Rs. 504 crores for Q1 FY 2016-17 vs Rs. 491 crores showing 3% growth for the same period last year. Discontinuance of certain promotional schemes and hygiene initiatives has impacted the business in short term however it will have positive impact in long term.

Brazil Business

- Brazilian business recorded revenues of Rs. 167 crores for Q1 FY 2016-17 vs Rs. 138 crores for the same period last year, showing 21% growth. The growth in Real is 31%.

USA

- US business recorded revenues of Rs. 434 crores for Q1 FY 2016-17 vs Rs. 888 crores for the same period last year.
- Previous period include exceptional revenues, primarily on account of the launch of a new product which had limited competition.

Germany

- German business recorded revenues of Rs. 187 crores for Q1 FY 2016-17 vs Rs. 157 crores for the same period last year.

About Torrent Pharma

Torrent Pharma, with annual revenues of more than Rs. 6600 crores is the flagship Company of the Rs. 18,300 crore Torrent Group.

Torrent Pharma continues to be at the forefront of the Indian pharmaceutical industry with many of its products ranking among the top 500 brands (AIOCD Dataset) in India. Its widespread international presence also includes several markets where Torrent is amongst the leading pharmaceutical companies in the respective countries.

Torrent has a fully equipped Research Center, employing almost 900 scientists, to support the Company's operations and product pipeline for both Domestic and Overseas markets. The Company's manufacturing plants located at Indrad, Baddi, Sikkim, Dahej and Pithampur have facilities to produce Formulations and Bulk drugs. The plants are approved by authorities from various regulated and semi regulated markets like US, UK, Brazil, Germany, Australia and South Africa.